American Journal of Obstetrics & Gynecology
Volume 189, Issue 1 , Pages 280-294 , July 2003

Endometriosis and ovarian cancer: Thoughts on shared pathophysiology

Received 13 November 2002 ,Revised 27 January 2003 ,Accepted 12 March 2003.

References 

  1. Halme J, Hammond MG, Hulka JF, Raj SG, Talbert LM. Retrograde menstruation in healthy women and in patients with endometriosis. Obstet Gynecol. 1984;64:151–154
  2. Eskanazi B, Warner ML. Epidemiology of endometriosis. Obstet Gynecol Clin North Am. 1997;24:235–259
  3. Lauchlan SC. The secondary mullerian system revisited. Int J Gynecol Pathol. 1994;13:73–79
  4. Heaps JM, Nieberg RK, Berek JS. Malignant neoplasms arising in endometriosis. Obstet Gynecol. 1990;75:1023–1028
  5. Sainz De La Cuesta R, Eichhorn JH, Rice LW, Fuller AF, Nikni N, Goff BA. Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol. 1996;60:238–244
  6. Vercellini P, Parazzini F, Bolis G, Carinelli S, Dindelli M, Vandola N, et al.  Endometriosis and ovarian cancer. Am J Obstet Gynecol. 1993;169:181–182
  7. LaGrenade A, Silverberg SG. Ovarian tumors associated with atypical endometriosis. Hum Pathol. 1988;19:1980–1984
  8. Moll UM, Chumas JC, Chalas E, Mann WJ. Ovarian carcinoma arising in atypical endometriosis. Obstet Gynecol. 1990;75:537–539
  9. Jimbo H, Yoshikawa H, Onda T, Yasugi T, Sakamoto A, Taketani Y. Prevalence of ovarian endometriosis in epithelial ovarian cancer. Int J Gynecol Obstet. 1997;59:245–250
  10. DePriest PD, Banks ER, Powell DE, van Nagell JR, Gallion HH, Pul SE, et al.  Endometrioid carcinoma of the ovary and endometriosis: the association in postmenopausal women. Gynecol Oncol. 1992;47:71–75
  11. Stern RC, Dash R, Bentley RC, Snyder MJ, Honey AF, Robbey SJ. Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol. 2001;133–139
  12. Mostoufizadeh M, Scully RE. Malignant tumors arising in endometriosis. Clin Obstet Gynecol. 1980;23:951–963
  13. Sampson JA. Endometrial carcinoma of the ovary arising in endometrial tissue in that organ. Arch Surg. 1925;10:1–72
  14. Hitti IF, Glasberg SS, Lubicz S. Clear cell carcinoma arising in extra ovarian endometriosis: report of three cases and review of the literature. Gynecol Oncol. 1990;39:314–320
  15. Erzen M, Kovacic J. Relationship between endometriosis and ovarian cancer. Eur J Gynaecol Oncol. 1998;6:553–555
  16. Friedlander ML. Prognostic factors in ovarian cancer. Semin Oncol. 1998;25:305–314
  17. Fukanaga M, Nomura K, Ishikawa E, Ushigome S. Ovarian atypical endometriosis: its close association with malignant epithelial tumors. Histopathology. 1997;30:249–255
  18. Yoshikawa H, Jimbo H, Okada S, Matsumoto K, Onda T, Yasugi T, et al.  Prevalence of endometriosis in ovarian cancer. Gynecol Obstet Investig. 2000;50:11–17
  19. Czernobilsky B, Morris WJ. A histologic study of ovarian endometriosis with emphasis on hyperplastic and atypical changes. Obstet Gynecol. 1979;53:311–323
  20. Jiang X, Hitchcock A, Bryan EJ, Watson RH, Englefield P, Thomas EJ, et al.  Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci. Can Res. 1996;56:3439–3459
  21. Jiang X, Morland SJ, Hitchcock A, Thomas EJ, Campbell IG. Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Can Res. 1998;58:1707–1712
  22. Martini M, Ciccarone M, Garganese G, Maggiore C, Evangelista A, Rahimi S, et al.  Possible involvement of hMLH1, p16 INK4a and PTEN in the malignant transformation of endometriosis. Int J Cancer. 2002;102:398–406
  23. Brinton LA, Gridley G, Persson I, Baron J, Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol. 1997;176:572–579
  24. Duczman L, Ballweg ML. Endometriosis and cancer: what is the connection?. Volume 20. Milwaukee (WIS): Endometriosis Association Newsletter; 1999;
  25. Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE, et al.  Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology. 2000;11:111–117
  26. Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ. Infertility, fertility drugs and ovarian cancer: a pooled analysis of case-control studies. Am J Epidiol. 2002;155:217–224
  27. Cahill DJ, Hull MGR. Pituitary-ovarian dysfunction and endometriosis. Hum Reprod Update. 2000;6:56–66
  28. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. N Engl J Med. 1994;331:771–776
  29. Ron E, Lunenfeld B, Menczer J, Blumstein T, Katz L, Oelsner G, et al.  Cancer incidence in a cohort of infertile women. Am J Epidemiol. 1987;125:780–790
  30. Venn A, Watson L, Lumley J, Giles G, King C, Healy D. Breast and ovarian cancer incidence after infertility and in vitro tertilization. Lancet. 1995;346:995–1000
  31. Hill AB. The environment and disease: association or causation?. Proc R Soc Med. 1965;58:295–300
  32. Christensen S, Hagen TM, Shigenaga MK, Ames BN. Chronic inflammation, mutation, and cancer. In:  Parsonnet J editors. Microbes and malignancy: infection as a a cause of human cancers. New York (NY): Oxford University Press; 1999;p. 35–88
  33. Ames BN, Gold LS, Wilett WC. The causes and prevention of cancer. Proc Natl Acad Sci U S A. 1995;92:5258–5265
  34. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?. Lancet. 2001;357:539–545
  35. O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer. 2001;85:273–283
  36. Ness RB, Cottreau C. Possible role of pelvic inflammation in ovarian cancer. J Natl Cancer Inst. 1999;91:1459–1467
  37. Graham J, Graham R. Ovarian cancer and asbestos. Environ Res. 1967;1:115–128
  38. Keal EE. Asbestosis and abdominal neoplasma. Lancet. 1960;2:1211–1216
  39. Acheson ED, Gardner MJ, Pippard EC, Grime LP. Mortality of two groups of women who manufactured gas masks from chrysotile and croadolite asbestos: a 40 year follow-up. Br J Ind Med. 1982;39:344–348
  40. Newhouse ML, Berry G, Wagner JC, Turok ME. A study of mortality of female asbestos workers. Br J Ind Med. 1972;29:134–141
  41. Newhouse ML, Berry G, Wagner JC. Mortality of factory workers in East London 1933-80. Br J Ind Med. 1985;42:4–11
  42. Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case control study. Br J Cancer. 1989;60:592–598
  43. Cook LS, Lamb ML, Weiss NS. Perineal powder exposure and the risk of ovarian cancer. Am J Epidemiol. 1997;145:459–465
  44. Cramer DW, Welch WR, Scully RE, Wojciechowski CA. Ovarian cancer and talc: a case-control study. Cancer. 1982;50:372–376
  45. Whittemore AS, Wu ML, Paffenbarger PS, Sarles DL, Kampert JB, Grosser S, et al.  Personal and environmental characteristics related to epithelial ovarian cancer, II: exposures to talcum powder, tobacco, alcohol, and coffee. Am J Epidemiol. 1988;128:1228–1240
  46. Harlow BL, Weiss NS, Roth GJ, Chu J, Daling JR. Case-control study of borderline ovarian tumors: reproductive history and exposure to exogenous female hormones. Cancer Res. 1988;48:5849–5852
  47. Hartge P, Hoover R, Lesher LP, McGowan L. Talc and ovarian cancer. [letter] JAMA. 1988;250:1844
  48. Tzonou A, Polychronopoulou A, Hsieh C, Rebelakos A, Karakatsani A, Trichopoulos D. Hair dyes, analgesics, tranquilizers, and perineal talc application as risk factors for ovarian cancer. Int J Cancer. 1993;55:408–410
  49. Shu WO, Brinton LA, Gao YT, Yuan JM. Population-based case-control study in Shanghai. Cancer Res. 1989;49:3670–3674
  50. Risch HA, Howe GR. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biol Prev. 1995;4:447–451
  51. Weiss NS, Harlow BL. Why does hysterectomy without bilateral oophorectomy influence the subsequent incidence of ovarian cancer?. Am J Epidemiol. 1986;124:856–858
  52. Cramer DW, Xu H. Epidemiologic evidence for uterine growth factors in the pathogenesis of ovarian cancer. Ann Epidemiol. 1995;5:310–314
  53. Hankinson SE, Hunter DJ, Colditz GA, Willett WC, Stampfer MJ, Rosner B, et al.  Tubal ligation, hysterectomy, and risk of ovarian cancer. JAMA. 1993;270:2813–2818
  54. Miracle-McMahill HL, Calle EE, Kosinski AS, Rodriguez C, Wingo PA, Thun MJ, et al.  Tubal ligation and fatal ovarian cancer in a large prospective cohort study. Am J Epidemiol. 1997;145:349–357
  55. Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol. 1994;140:585–597
  56. Green A, Purdie D, Bain C, Siskind V, Russell P, Quinn M, et al.  Tubal sterilization, hysterectomy and decreased risk of ovarian cancer. Int J Cancer. 1997;71:948–951
  57. Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER. Over-the-counter analgesics and risk of ovarian cancer. Lancet. 1998;351:104–107
  58. Rosenberg L, Palmer JR, Sowmya Rao R, Coogan PF, Strom BL, Zawber AG, et al.  A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2000;9:933–937
  59. Tavani A, Gallus S, La Vecchia C, Conti E, Montella M, Franceschi S. Aspirin and ovarian cancer: an Italian case-control study. Ann Oncol. 2000;11:1171–1173
  60. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL, Shore RE. Aspirin and epithelial ovarian cancer. Prev Med. 2001;33:682–687
  61. Cramer DW, Hutchison GB, Welch WR, Scully RE, Ryan KJ. Determinants of ovarian cancer risk, I: reproductive experiences and family history. J Natl Cancer Inst. 1983;71:711–716
  62. Risch HA, Marrett LD, Jain M, Howe GR. Differences in risk factors for epithelial ovarian cancer by histologic type: results of a case-control study. Am J Epidemiol. 1996;144:363–372
  63. McGowan L, Parent L, Lednar W, Norris HJ. The women at risk for developing ovarian cancer. Gynecol Oncol. 1979;7:325–344
  64. Gwinn ML, Lee NC, Rhoses PH, Layde PM, Rubin GL. Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol. 1990;6:559–568
  65. Wu ML, Whittmore AS, Paffengarger RS, Sarles DL, Kampert JB, Grosser S, et al.  Personal and environmental characteristics related to epithelial ovarian cancer, I: reproductive and menstrual events and oral contraceptive use. Am J Epidemiol. 1988;128:1216–1227
  66. Mori M, Harabuchi I, Miyake H, Casagrande JT, Henderson BE, Ross RK. Reproductive, genetic, and dietary risk factors for ovarian cancer. Am J Epidemiol. 1988;128:771–777
  67. Fathalla MF. Incessant ovulation-a factor in ovarian neoplasia?. Lancet. 1971;2:163
  68. Adashi EY. The potential role of interleukin-1 in the ovulatory process: an evolving hypothesis. Mol Cell Endocrinol. 1998;140:77–81
  69. Probert L, Plows D, Kontogeorgos G, Kollias G. The type-i interleukin-1 receptor acts in series with tumor-necrosis-factor (TNF) to induce arthritis in tnf-transgenic mice. Eur J Immunol. 1995;25:1794–1797
  70. Hillier SG, Tetsuka M. An anti-inflammatory role for glucocorticoids in the ovaries. J Reprod Immunol. 1998;39:21–27
  71. Ziltener HJ, Maines-Bandiera S, Schrader JW, Aversperg N. Secretion of bioactive IL-1, IL-6 and colony stimulating factors by human ovarian surface epithelium. Biol Reprod. 1993;49:635–641
  72. Auersperg N, Maines-Bandiera SL, Dyck HG. Ovarian carcinogenesis and the biology of ovarian surface epithelium. J Cellular Physiol. 1997;173:261–265
  73. Espey LL. Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction. Biol Reprod. 1994;50:233–238
  74. Smith G, Roberts R, Hall C, Nuki G. Reversible ovulatory oailure associated with the development of luteinized unruptured follices in women with inflammatory arthritis taking non-steroidal anti-inflammatory drugs. Br J Rheumatol. 1996;35:458–462
  75. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001;411:375–379
  76. Naylor MS, Stamp GWH, Foulkes WD, Eccles D, Balkwill FR. Tumor necrosis factor and its receptors in human ovarian cancer. J Clin Invest. 1993;91:2194–2206
  77. Burke F, Relf M, Negus R, Balkwill F. Acytokine profile of normal and malignant ovary. Cytokine. 1996;8:578–585
  78. Asschert JG, Vellenga E, Ruiters MH. Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines. Int J Cancer. 1999;82:244–249
  79. Malik STA, Griffin DB, Fiers W, Balkwill FR. Paradoxical, effects of tumour necrosis factors in experimental ovarian cancer. Int J Cancer. 1989;44:918–925
  80. Murdoch WJ. Ovarian surface epithelium, ovulation and carcinogenesis. Biol Rev Camb Philos Soc. 1996;71:529–543
  81. Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R, et al.  Contributions to stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst. 2002;94:1134–1142
  82. Harada T, Iwabe T, Terakawa N. Role of cytokines in endometriosis. Fertil Steril. 2001;76:1–10
  83. Nothnick WB. Treating endometriosis as an autoimmune disease. Fertil Steril. 2001;76:223–231
  84. Gazvani R, Templeton A. New considerations for the pathogenesis of endometriosis. Int J Gynecol Obstet. 2002;76:117–126
  85. Oosterlynck DJ, Cornillie FJ, Waer M, Vandeputte M, Konincky PR. Women with endometriosis show a defect in natural killer activity resulting in a decreased cytotoxicity to autologous endometrium. Fertil Steril. 1991;56:45–51
  86. Wilson TJ, Hertzog PJ, Angus D, Munnery L, Wood EC, Kola I. Decreased natural killer cell activity in endometriosis patients: relationship to disease pathogenesis. Fertil Steril. 1994;62:1086–1088
  87. Ho HN, Chao KH, Chen HF, Wu MY, Yang YS, Lee TY. Peritoneal natural killer cytotoxicity and CD25+CD3+ lymphocyte subpopulation are decreased in women with stage III-IV endometriosis. Hum Reprod. 1995;10:2671–2675
  88. Kikuchi Y, Ishikwa N, Hirata J, Imaizumi E, Sasa H, Nagata I. Changes in peripheral blood lymphocyte subsets before and after operation of patients with endometriosis. Acta Obstet Gynecol Scand. 1993;72:157–161
  89. Haney AF, Muscato JJ, Weinberg JB. Peritoneal fluid cell populations in infertility patients. Fertil Steril. 1981;35:696–698
  90. Halme J, Becker S, Hammond MG, Raj S. Pelvic macrophages in normal and infertile women: the role of patent tubes. Am J Obstet Gynecol. 1982;142:890–895
  91. Halme J, Becker S, Wing R. Accentuated cyclic activation of peritoneal macrophages in patients with endometriosis. Obstet Gynecol. 1984;148:85–90
  92. Halme J, Becker S, Haskill S. Altered maturation and function of peritoneal macrophages: possible role in the pathogenesis of endometriosis. Am J Obstet Gynecol. 1987;156:783–789
  93. Dunselman GAJ, Hendrix MGR, Bouckaert PXJ, Evers JLH. Functional aspects of peritoneal macrophages in endometriosis of women. J Reprod Fertil. 1988;82:707–710
  94. Braun DP, Muriana A, Gebel H, Rotman C, Dmowksi WP. Monocyte mediated enhancement of endometrial cell proliferation in women with endometriosis. Fertil Steril. 1994;61:78–84
  95. Oosterlynck D, Meuleman M, Waer M, Koninckx P. Transforming growth factor-β activity is in peritoneal fluid from women with endometriosis. Obstet Gynecol. 1994;83:287–292
  96. McLaren J, Prentice A, Charnock-Jones DS, Smith SK. Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod. 1996;11:220–223
  97. Oosterlynck DJ, Meuleman H, Sobis M, Vandeputte M, Koninckx PR. Angiogenic activity of peritoneal fluid from women with endometriosis. Fertil Steril. 1993;59:778–782
  98. Rodgers WH, Osteen KG, Matrisian LM, Navre M, Gorstein F. Expression and localization of matrilysin, a matrix metalloproteinase, in the human endometrium. Am J Obstet Gynecol. 1993;168:253–260
  99. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145–173
  100. Sheng J, Shao JD, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998;58:362–366
  101. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis, II. J Natl Cancer Inst. 1998;90:1609–1620
  102. Vane JR, Bakhle YS, Bottin RM. Cyclooxygenases 1 and 2. Ann Rev Pharmacol Toxicol. 1998;38:97–120
  103. Hsu CC, Yang BC, Wu MH, Huang KE. Enhanced interleukin-4 expression in patients with endometriosis. Fertil Steril. 1997;67:1059–1064
  104. Akoum A, Lemay A, Paradis I, Rheault N, Maheux R. Secretion of interleukin-6 by human endometriotic cells and regulation by proinflammatory cytokines and sex steroids. Hum Reprod. 1996;11:2269–2275
  105. Tseng JF, Ryan IP, Milam TD, Murao JT, Schriock ED, Landers DV, et al.  Interleukin-6 secretion in vitro is up-regulated in ectopic and autopic endometrial stromal cells from women with endometriosis. J Clin Endocrinol Metab. 1996;81:1118–1122
  106. Tsudo T, Harada T, Iwabe T, Tanikawa M, Nagano Y, Ito M, et al.  Altered gene expression and secretion of interleukin-6 in stromal cells derived from endometriotic tissues. Fertil Steril. 2000;73:205–211
  107. Kharfi A, Boucher A, Akoum A. Abnormal interleukin-1 receptor type II gene expression in the endometrium of women with endometriosis. Biol Reprod. 2002;66:401–406
  108. Gleicher N, el-Roeiy A, Confino E, Friberg J. Is endometriosis an autoimmune disease?. Obstet Gynecol. 1987;70:115–122
  109. Sinaii N. Autoimmune and related diseases among women with endometriosis: a survey analysis. Hum Reprod. 2002;17:2715–2724
  110. Startseva NV. Clinicoimmunological aspects of genital endometriosis. Akush Ginekol Mosk. 1980;3:23–26
  111. Weed JC, Arquembourg PC. Endometriosis: can it produce an autoimmune response resulting in infertility?. Clin Obstet Gynecol. 1980;23:885–893
  112. Mathur S, Peress MR, Williamson HO, Youmans CD, Manye SA, Garvin AJ, et al.  Autoimmunity to endometrium and ovary in endometriosis. Clin Exp Immunol. 1982;50:259–266
  113. El-Roeiy A, Dmowski WP, Gleicher N, Radwanska E, Harlow L, Binor Z, et al.  Danazol but not gonadotropin-releasing hormone agonists suppress autoantibodies in endometriosis. Fertil Steril. 1988;50:864–871
  114. Kennedy SH, Kstarkey PM, Sargent IL, Hicks BR, Barlow DH. Antiendometrial antibodies in endometriosis measured by an enzyme-linked, immunosorbent assay before and after treatment with danazol and nafarelin. Obstet Gynecol. 1990;75:914–918
  115. Imai A, Takagai A, Tamaya T. Gonadotropin-releasing hormone analog repairs reduced endometrial cell apoptosis in endometriosis in vitro. Am J Obstet Gynecol. 2000;182:1142–1146
  116. Clerci M, Shearer GM, Clerici E. Cytokine dysregulation in invasive cervical carcinoma and other human neoplasias: time to consider the TH1/TH2 paradigm. J Natl Cancer Inst. 1998;90:261–263
  117. Steinleitner A, Lambert H, Roy S. Immunodulation with pentoxifylline abrogates macrophage-mediated infertility in an in vivo model: a paradigm for a novel approach to the treatment of endometriosis-assoicated subfertility. Fertil Steril. 1991;55:26–31
  118. Balasch J, Creus M, Fabregues F, Carmona F, Martinez-Roman S, Manau D, et al.  Pentoxifylline versus placebo in the treatment of infertility associated with minimal or mild endometriosis: a pilot randomized clinical trial. Hum Reprod. 1997;12:2046–2050
  119. Nothnick WB, Curry TE, Vernon MW. Immunomodulation of rat endometriotic implant growth and protein production. Am J Reprod Immunol. 1994;31:151–162
  120. Cramer DW, Welch WR. Determinants of ovarian cancer risk, II: inferences regarding pathogenesis. J Natl Cancer Inst. 1983;71:717–721
  121. Tzonou A, Day NE, Trichopoulos D, Walker A, Saliaraki M, Papapostolou M, et al.  The epidemiology of ovarian cancer in Greece: a case-control study. Eur J Cancer Clin Oncol. 1984;20:1045–1052
  122. Hildreth NG, Kelsey JL, LiVolsi VA, Fisher DB, Holford TR, Mostow ED, et al.  An epidemiology study of epithelial carcinoma of the ovary. Am J Epidemiol. 1981;114:398–405
  123. Newhouse ML, Pearson RM, Fullerton JM, Boeson EA, Shannon HS. A case control study of the ovary. Br J Prev Soc Med. 1977;31:148–153
  124. Wu L, Einstein M, Geissler WM, Chan HK, Elliston KO, Andersson S. Expression cloning and characterization of human 17β-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20α-hydroxysteroid dehydrogenase activity. J Biol Chem. 1993;268:12964–12969
  125. Casagrande JT, Louie EW, Pike MC, Roy S, Ross RK, Henderson BE. “Incessant ovulation” and ovarian cancer. Lancet. 1979;2:170–173
  126. Rosenberg L, Shapiro S, Slone D, Kaufman DW, Helmrich SP, Miettinen OS, et al.  Epithelial ovarian cancer and combination oral contraceptives. JAMA. 1982;247:3210–3212
  127. Kvale G, Heuch I, Nilssen S, Beral V. Reproductive factors and risk of ovarian cancer: a prospective study. Int J Cancer. 1988;42:246–251
  128. Joly DJ, Lilienfeld AM, Diamond EL, Bross IDJ. An epidemiologic study of the relationship of reproductive experience to cancer of the ovary. Am J Epidemiol. 1974;99:190–209
  129. Nasca PC, Greenwald P, Chorost S, Richart R, Caputo T. An epidemiologic case-control study of ovarian cancer and reproductive factors. Am J Epidemiol. 1984;119:705–713
  130. Franceschi S, LaVecchia C, Helmrich SP, Mangioni C, Tognoni G. Risk factors for epithelial ovarian cancer in Italy. Am J Epidemiol. 1982;115:714–719
  131. La Vecchia C, Decarli A, Franceshi S, Regallo M, Tognoni G. Age at first birth and the risk of epithelial ovarian cancer. J Natl Cancer Inst. 1984;73:663–666
  132. Risch HA, Weiss NS, Lyon JL, Daling JR, Liff JM. Events of reproductive life and the incidence of epithelial ovarian cancer. Am J Epidemiol. 1983;117:128–139
  133. Voigt LF, Harlow BL, Weiss NS. The influence of age at first birth and parity on ovarian cancer risk. Am J Epidemiol. 1986;124:490–491
  134. Mori M, Kiyosawa H, Miyake H. Case-control study of ovarian cancer in Japan. Cancer. 1984;53:2746–2752
  135. Wynder EL, Dodo H, Barber HRK. Epidemiology of cancer of the ovary. Cancer. 1969;23:352–370
  136. Hankinson SE, Colditz GA, Hunter DJ, Willett WC, Stampfer MJ, Rosner B, et al.  A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer. 1995;76:284–290
  137. Adami HO, Hsieh CC, Lambe M, Trichopoulos D, Leon D, Persson I, et al.  Parity, age at first childbirth, and risk of ovarian cancer. Lancet. 1944;344:1250–1254
  138. Chen MT, Cook LS, Daling JR, Weiss NS. Incomplete pregnancies and risk of ovarian cancer (Washington, United States). Cancer Causes Control. 1996;7:415–420
  139. Whittemore AS, Harris R, Itnyre J, Collaborative Ovarian Cancer Group . Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. Am J Epidemiol. 1992;136:1184–1203
  140. Purdie D, Green A, Bain C, Siskind V, Ward B, Hacker N. Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Int J Cancer. 1995;62:678–684
  141. Riman T, Dickman PW, Nilsson S, Correia N, Nordliner H, Magnusson CM, et al.  Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst. 2002;94:497–504
  142. Hartge P, Schiffman MH, Hoover R, McGowan L, Lesher L, Norris HJ. A case-control study of epithelial ovarian cancer. Am J Obstet Gynecol. 1989;161:10–16
  143. Cancer , Steroid Hormone Study of the Centers for Disease Control , the National Institute of Child Health , Human Development . The reduction in risk of ovarian cancer associated with oral-contraceptive use. N Engl J Med. 1987;316:650–655
  144. WHO Collaborative Study of Neoplasia , Steroid Contraceptives . Epithelial ovarian cancer and combined oral contraceptives. Int J Epidemiol. 1989;18:538–545
  145. Beral V, Hannaford P, Kay C. Oral contraceptive use and malignancies of the genital tract. Lancet. 1988;2:1331–1334
  146. Willett WC, Bain C, Hennekens CH, Rosner B, Speizer FE. Oral contraceptives and the risk of ovarian cancer. Cancer. 1981;48:1684–1687
  147. Vessey M, Metcalfe A, Wells C, McPherson K, Westhoff C, Yates D. Ovarian neoplasms, functional ovarian cysts, and oral contraceptives. BMJ. 1987;294:1518–1520
  148. Cramer DW, Hutchison GB, Welch WR, Scully RE, Knapp RC. Factors affecting the association of oral contraceptives and ovarian cancer. N Engl J Med. 1982;307:1047–1051
  149. Weiss NS, Lyon JL, Liff JM, Vollmer WM, Daling JR. Incidence of ovarian cancer in relation to the use of oral contraceptives. Int J Cancer. 1981;28:669–671
  150. La Vecchia C, Franceschi S, Decarli A. Oral contraceptives and the risk of epithelial ovarian cancer. Br J Cancer. 1984;50:31–34
  151. Parazzini F, La Vecchia C, Negri E, Bocciolone L, Fedele L. Oral contraceptive use and the risk of ovarian cancer: another Italian case-control study. Eur J Cancer. 1991;27:594–598
  152. Stanford JL. Oral contraceptives and neoplasia of the ovary. Contraception. 1991;43:543–556
  153. Ness RB, Grisso JA, Klapper J, Schlesselman JJ, Silberzweig S, Vergona R, et al.  Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. Am J Epidemiol. 2000;152:233–241
  154. Schildkraut JM, Calingaert B, Marchbanks PA. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst. 2002;94:32–38
  155. Riman T, Dickman PW, Nilsson S, Correia N, Nordliner H, Magnusson CM, et al.  Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol. 2002;156:363–373
  156. Whittemore AS, Harris R, Itnyre J, Collaborative Ovarian Cancer Group . Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. Am J Epidemiol. 1992;136:1212–1220
  157. Glud E, Kjaer SK, Troisi R, Brinton LA. Fertility drugs and ovarian cancer. Epidemiol Rev. 1998;20:237–257
  158. Bristow RE, Karlan BY. Ovulation induction, infertility, and ovarian cancer risk. Fertil Steril. 1996;66:499–507
  159. Helzlsouer KJ, Alberg AJ, Gordon GB, Longcope C, Bush TL, Hoffman SC, et al.  Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA. 1995;274:1926–1930
  160. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Pettersson KS, Huhtaniemi IT. Luteinizing hormone, its beta-subunit variant, and epithelial ovarian cancer: the gonadotrophin hypothesis revisited. Am J Epidemiol. 2001;154:43–49
  161. Lau KM, Mok SC, Ho SM. Expression of human estrogen receptor alpha and beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci U S A. 1999;96:5722–5727
  162. Choi KC, Kang SK, Tai CJ, Auersperg N, Leung PC. Estradiol up-regulates antiapoptotic Bc1-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Endocrinology. 2001;142:2351–2360
  163. Pujol P, Rey JM, Nirde P, et al.  Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. Can Res. 1998;58:5367–5373
  164. Chu S, Mamers P, Burger HG, Fuller PJ. Estrogen receptor isoform gene expression in ovarian stromal and epithelial tumors. J Clin Endocrinol Metab. 2000;85:1200–1205
  165. Fujimoto J, Hirose R, Sakaguchi H, Tamya T. Clinical significance of expression of estrogen receptor alpha and beta mRNAs in ovarian cancers. Oncol. 2000;58:334–341
  166. Rutherford T, Brown WD, Sapi E, Aschkenazi S, Munoz A, Mor G. Absence of estrogen receptor-beta expression in metastatic ovarian cancer. Obstet Gynecol. 2000;96:417–421
  167. Brandenberger AW, Tee MK, Jaffe RB. Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. J Clin Endocrinol Metab. 1998;83:1025–1028
  168. Karasik A, Menczer J, Pariente C, Kanety H. Insulin-like growth factor I (IGF-I) and IGF-binding protein-2 are increased in cyst fluid of epithelial ovarian cancer. J Clin Endocrinol Metab. 1994;126:271–276
  169. Jeppsson S, Kullander S, Rannevik G. Peripheral and ovarian venous concentrations of gonadal steroids and CEA in women with ovarian tumors. Acta Obstet Gynecol Scand. 1982;61:209–212
  170. Waksmanski B, Dudkiewicz , Kowalski T. Changes in insulin-like growth factor, 17-β-estradiol, and progesterone in postmenopausal women with benign and malignant ovarian tumors. Med Sci Monit. 2001;7:919–923
  171. Cramer DW, Barbieri RL, Fraer AR, Harlow BL. Determinants of early follicular phase gonadotrophin and estradiol concentrations in women of late reproductive age. Hum Reprod. 2002;17:221–227
  172. Liu J, Rebar RW, Yen SSC. Neuroendocrine control of the postpartum period. Clin Perinatol. 1983;10:723–736
  173. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. Review. J Natl Cancer Inst. 1998;90:1774–1786
  174. Parazzini F, La Vecchia C, Negri E, Gentile A. Menstrual factors and the risk of epithelial ovarian cancer. J Clin Epidemiol. 1989;42:443–448
  175. Cottreau CM, Ness RB, Kriska AM. Physical activity and the reduced risk of ovarian cancer. Obstet Gynecol. 2000;96:609–614
  176. Bertone ER, Willett WC, Rosner BA, Hunter DJ, Fuchs CS, Speizer FG. Prospective study of recreational physical activity and ovarian cancer. J Natl Cancer Inst. 2001;93:942–948
  177. Fairfield KM, Willett WC, Rosner BA, Manson JE, Speizer FE, Hankinson SE. Obesity, weight gain, and ovarian cancer. Obstet Gynecol. 2002;100:288–296
  178. Lukanova A, Toniolo P, Lundin E, Micheli A, Akhmedkhanov A, Miti P, et al.  Body mass index in relation to ovarian cancer: a multi-centre nested case-control study. Int J Cancer. 2002;99:603–608
  179. Kuper H, Titus-Ernstoff L, Harlow BL, Cramer DW. Population based study of coffee, alcohol and tobacco use and risk of ovarian cancer. Int J Cancer. 2000;88:313–318
  180. Risch HA. Hormone replacement therapy and the risk of ovarian cancer. [letter] Gynecol Oncol. 2002;86:115–117
  181. Rodriquez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA. 2001;285:1460–1465
  182. Lacey JV, Lubin J, Sherman M, Schatzkin A, Mink P, Hartge P. Menopausal hormone replacement therapy and risk of ovarian cancer in a prospective study. JAMA. 2002;288:334–341
  183. Rosenberg L, Palmer JR, Zauber AG, Warshaver MC, Lewis JL, Strom BL, et al.  A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol. 1994;139:654–661
  184. Whiteman D, Murphy M, Cook L, Cramer D, Hartge P, Marchbanks P, et al.  Multiple births and risk of epithelial ovarian cancer. J Natl Cancer Inst. 2000;152:233–241
  185. Zeimet AG, Muller-Holzner E, Marth C, Daxenbichler G. Immunocytochemical versus biochemical receptor determination in normal and tumorous tissues of the female reproductive tract and the breast. JAMA. 1994;49:365–372
  186. Svelda P, Denison U, Schemper M, Spona J, Vavra N, Salazar H. Oestrogen and progesterone receptor content as a prognostic factor in advanced epithelial ovarian carcinoma. Br J Obstet Gynaecol. 1990;97:706–712
  187. Fujimura M, Hidaka T, Kataoka K, Yamakawa Y, Akada S, Teranishi A, et al.  Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma. Am J Surg Pathol. 2001;25:667–672
  188. Rodriguez C, Nagarsheth NP, Lee KL, Bentley RC, Walmer DK, Cline M, et al.  Progestin-induced apoptosis in the macaque ovarian epithelium: differential regulation of transforming growth factor-β. J Natl Cancer Inst. 2002;94:50–59
  189. McNatty KP, Makris A, Reinhold VN, De Grazin C, Osathanondh R, Ryan KJ. Metabolism of androstenedione by human ovarian tissues in vitro with particular reference to reductase and aromatase activity. Steroids. 1979;34:429–443
  190. Slotman BJ, Rao BR. Response to inhibition of androgen action of human ovarian cancer cells in vitro. Cancer Lett. 1989;45:312–320
  191. Chadha S, Rao BR, Slotman BE, Van Vroonhoven CS, Van der Kwast TH. An immunohistochemical evaluation of androgen and progesterone receptors in ovarian cancer. Hum Pathol. 1993;24:90–95
  192. Nishizuka Y, Sakakura T, Tsujimura T, Matsumoto K. Steroid biosynthesis in vitro by dysgenetic ovaries induced by neonatal thymectomy in mice. Endocrinology. 1973;93:786–792
  193. Murphy A, Cropp CS, Smith BS, Burkman RT, Zacur HA. Effect of low-dose oral contraceptives on gonotropins, androgens, and sex hormone binding globulin in non-hirsuite women. Fertil Steril. 1990;53:34–39
  194. van der Vange N, Blankenstein MA, Kloosterboer HJ, Haspels AA. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, tubal and free testosterone. Contraception. 1990;41:345–352
  195. Mink PJ, Folsom AR, Sellers TA, Kushi LH. Physical activity, waist-to-hip ratio and other risk factors for ovarian cancer: a follow-up study of older women. Epidemiology. 1996;7:15–38
  196. Schildkraut JM, Schwingl PJ, Bastos E, Evanoff A, Huges C. Epithelial ovarian cancer risk among women with polycystic ovarian syndrome. Obstet Gynecol. 1996;88:549–554
  197. Cottreau CM, Ness RB, Goodman MT. Endometriosis and its treatment with danazol or leuprolide in relationship to ovarian cancer. In: Proceedings of the annual meeting of the Society of Gynecologic Oncology; 2002 March; Miami, Fla. Miami: The Society; 2002;
  198. Lukanova A, Lundin E, Toniolo P, Micheli A, Akmedkhanov A, Rinaldi S, et al.  Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer. 2002;101:549–554
  199. Cramer DW, Missmer SA. The epidemiology of endometriosis. Ann N Y Acad Sci. 2002;955:11–22
  200. Cramer DW, Wilson E, Stillman RJ. The relation of endometriosis to menstrual characteristics, smoking, and exercise. JAMA. 1986;255:1904–1908
  201. Matorras R, Rodiquez F, Piuoan JI. Epidemiology of endometriosis in infertile women. Fertil Steril. 1995;63:34–38
  202. Moen MH, Schei B. Epidemiology of endometriosis in a Norwegian county. Acta Obstet Gynecol Scand. 1997;76:559–562
  203. Bérubé S, Marcoux S, Maheux R, Canadian Collaborative Group on Endometriosis . Characteristics related to the prevalence of minimal or mild endometriosis in infertile women. Epidemiolog. 1998;9:504–510
  204. Grodstein F, Goldman MB, Ryan L, Cramer DW. Relation of female infertility to consumption of caffeinated beverages. Am J Epidemiol. 1993;137:1353–1356
  205. Sangi-Haghpeykar H. Epidemiology of endometriosis to menstrual characteristics, smoking, and exercise. JAMA. 1986;255:1904–1908
  206. Signorllo LB, Harlow BL, Cramer DW. Epidemiologic determinants of endometriosis: a hospital-based case-control study. Ann Epidemiol. 1997;7:267–274
  207. Obermeyer CM, Armenian HK, Azoury R. Endometriosis in Lebanon. Am J Epidemiol. 1986;124:762–765
  208. Parazzini F, Ferraroni M, Fedele L. Pelvic endometriosis: reproductive and menstrual risk factors at different stages in Lombardy, northern Italy. J Epidemiol. 1995;49:61–64
  209. Gruppo Italiano per lo Studio dell endometriosi . Risk factors for pelvic endometriosis in women with pelvic pain or infertility. Eur J Obstet Gynecol Reprod Biol. 1999;83:195–199
  210. Vessey MP, Villard-Mackintosh L, Painter R. Epidemiology of endometriosis in women attending family planning clinics. BMJ. 1993;306:182–184
  211. Parazzini F, Ferraroni M. Epidemiology and endometriosis. BMJ. 1993;306:930–934
  212. Halme J, Stovall D. Endometriosis and its medical management. In:  Wallach EE,  Zacur HA editor. Reproductive medicine and surgery. St. Louis: Mosby; 1995;p. 692–710
  213. Hadfield RM, Yudkin PL, Coe CL, Scheffler J, Uno H, Barlow DH, et al.  Risk factors for endometriosis in the rhesus monkey (Macaca mulatta): a case-control study. Hum Reprod. 1997;3:109–115
  214. Zeitoun KM, Bulun SE. Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target. Fertil Steril. 1999;72:961–969
  215. Bulun SE, Mahendroo MS, Simpson ER. Polymerase chain reaction amplification fails to detect aromatase cytochrome P450 transcripts in normal human endometrium or deciduas. J Clin Endocrinol Metab. 1993;76:1458–1463
  216. Casey ML, MacDonald PC. Origin of estrogen and the regulation of estrogen formation in postmenopausal women. In:  Buchsbaum JH editors. The menopause. New York: Springer-Verlag; 1983;p. 1–8
  217. MacDonald PC, Rombaut RP, Siiteri PK. Plasma precursors of estrogen, I: extent of conversion of plasma Δ4-androstenedione to estrone in normal males and non-pregnant normal, castrate and adrenalectomized females. J Clin Endocrinol Metab. 1967;27:1103–1111
  218. Labrie Y, Durocher F, Lachance Y, Turgeon C, Simard J, Labne C, et al.  The human type II 17β-hydroxysteroid dehydrogenase gene encodes two alternatively spliced mRNA species. DNA Cell Biol. 1995;14:849–861
  219. Anderson S, Moghrabi N. Physiology and molecular genetics of 17β-hydroxysteroid dehydrogenases. Steroids. 1997;62:143–147
  220. Zeitoun KM, Takayama K, Sasano H, Suzuki T, Moghrabi N, Anderson S, et al.  Deficient 17β-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize estradiol-17β. J Clin Endocrinol Metab. 1998;83:4474–4480
  221. Osteen KG, Bruner KL, Sharpe-Timmis KL. Steroid and growth factor regulation of matrix metalloproteinase expression and endometriosis. Semin Reprod Endocrinol. 1996;14:247–255
  222. Bruner-Tran KL, Rier SE, Eisenberg E, Osteen KG. The potential role of environmental toxins in the pathophysiology of endometriosis. Gynecol Obstet Invest. 1999;48:45–56
  223. Huang JC, Liu DY, Yadollahi S, Wu KK, Dawood MY. Interleukin-1β induces cyclooxygenase-2 gene expression in cultured endometrial stromal cells. J Clin Endocrinol Metab. 1998;83:538–541
  224. Noble LS, Takayama K, Putman JM, Johns DA, Hinshelwood MM, Agarwal VR, et al.  Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. J Clin Endocrinoll Metab. 1997;82:600–606
  225. Kitawaki J, Noguchi T, Amatsu T, Maeda K, Tsukamoto K, Yamamoto T, et al.  Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium. Biol Reprod. 1997;57:514–519
  226. Osteen KG, Rodgers WH, Gaire M, Hargrove J, Gorstein F. Stromal-epithelial interaction mediates steroidal regulation of matrix metalloproteinase expression in the human endometrium. Proc Natl Acad Sci U S A. 1994;91:10129–10133
  227. Schatz F, Papp C, Toth-pal E, Lockwood C. Ovarian-steroid modulation of stromelysin-1 expression in human endometrial stroma and decidual cells. J Clin Endocrinol Metab. 1994;78:1467–1472
  228. Bruner KL, Matrisian LM, Rodgers WH, Gorstein F, Osteen KG. Suppression of matrix metalloproteinases inhibits establishment of ectopic lesions by human tissue in nude mice. J Clin Invest. 1997;99:2851–2857
  229. Jones RK, Searle RF, Bulmer JN. Apoptosis and BCL-2 expression in normal human endometriosis, endometriosis and adenomyosis. Hum Reprod. 1998;13:3496–3502
  230. Sasano H, Nobuhiro H. Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Endocr Rev. 1998;19:593–607
  231. Sasano H, Okamoto M, Mason JI, Simpson ER, Mendelson CR, Sasano N, et al.  Immunohistochemical studies of steroidogenic enzymes (aromatase, 17α-hydroxylase and cholesterol side-chain-cleavage cytochrome P-450) in sex-cord stromal tumors of the ovary. Hum Pathol. 1989;20:452–457
  232. Kaga K, Sasano H, Harada N, Ozaki M, Sato S, Yajima A. Aromatase in human common epithelial ovarian neoplasms. Am J Pathol. 1996;149:45–51
  233. Syed V, Ulinski G, Mok SC, Ho SM. Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. J Natl Cancer Inst. 2002;94:617–629
  234. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Askenazi Jews. N Engl J Med. 1997;336:1401–1408
  235. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three US population-based case-control studies of ovarian cancer. Am J Hum Genet. 1997;60:496–504
  236. Coxhead D, Thomas EJ. The familial inheritance of endometriosis in a British population: a case-control study. J Obstet Gynaecol. 1993;13:42–44
  237. Moen MH, Magnus P. The familial risk of endometriosis. Acta Obstet Gynecol Scand. 1993;72:560–564
  238. Kennedy S, Hadfield R, Westbrook C, Weeks DE, Barlow D, Golding S. Magnetic resonance imaging to assess familial risk in relatives of women with endometriosis. Lancet. 1998;352:1440–1441
  239. Hadfield RH, Mardon HJ, Barlow DH, Kennedy SH. Endometriosis in monozygotic twins. Fertil Steril. 1997;68:941–942
  240. Treloar SA, O'Connor DT, O'Connor VM, Martin NG. Genetic influences on endometriosis in an Australian twin sample. Fertil Steril. 1999;71:701–710
  241. Levine DA, Boyd J. The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series. Can Res. 2001;61:908–911
  242. Georgiou I, Syrrou M, Bouba I, Dalkalitis N, Paschopoulos M, Navrozoglou I, et al.  Association of estrogen receptor gene polymorphisms with endometriosis. Fertil Steril. 1999;72:164–166
  243. Kitawaki J, Obayashi H, Ishihara H, Koshiba H, Kusuki I, Kado N, et al.  Oestrogen receptor-alpha gene polymorphism is associated with endometriosis, adenomyosis and leiomyomata. Hum Reprod. 2001;16:51–55
  244. Menin C, Banna GL, De Salvo G, Lazzarotto V, De Nicolo A, Agata S, et al.  Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer. Cancer Lett. 2001;168:31–36
  245. Spurdle AB, Webb PM, Chen X, Martin NG, Giles GG, Hopper JL, et al.  Androgen receptor exon 1 CAG repeat length and risk of ovarian cancer. Int J Cancer. 2000;87:637–643
  246. Rowe SM, Coughlan SJ, McKenna NJ, Garrett E, Kieback DG, Carney DN, et al.  Ovarian carcinoma-associated TaqI restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an alu sequence insertion. Can Res. 1995;2743–2745
  247. Runnebaum IB, Wang-Gohrke S, Verprini D, Kreinberg R, Lynch H, Moslehi R, et al.  Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics. 2001;11:635–638
  248. McKenna NJ, Kieback DG, Carney DN, Fanning M, McLinden J, Headon DR. A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma. Br J Cancer. 1995;71:451–455
  249. Kieback DG, Gause HM, Korner W, et al.  A TaqI restriction fragment length polymorphism in the human progesterone receptor gene is associated with sporadic epithelial ovarian cancer and with breast cancer. J Soc Gynecol Investig. 1995;2:137
  250. Lancaster JM, Berchuck A, Carney ME, Wiseman R, Taylor JA. Progesterone receptor gene polymorphism and risk for breast and ovarian cancer. [letter] Br J Cancer. 1998;78:277–278
  251. Tong D, Fabjani G, Heinze G, Obermair A, Leodolter S, Zeillinger R. Analysis of the human progesterone receptor gene polymorphism progins in Austrian ovarian carcinoma patients. Int J Cancer. 2001;95:394–397
  252. Wieser F, Schneeberger C, Tong D, Tempfer C, Huber JC, Wenzl R. Progins receptor gene polymorphism is associated with endometriosis. Fertil Steril. 2002;77:309–312
  253. Modugno FM, Ness RB. Reproductive and familial risk factors for epithelial ovarian cancer according to histologic type. Ann Epidemiol. 2001;11:568–574
  254. Modugno FM, Ness RB, Vergona R. Cigarette smoking and the risk of mucinous and non-mucinous epithelial ovarian cancer. Epidemiology. 2002;13:467–471
  255. Wittenberg L, Cook LS, Rossing MA, Weiss NS. Reproductive risk factors for mucinous and nonmucinous epithelial ovarian cancer. Epidemiology. 1999;10:761–763
  256. Kaufman DW, Kelly JP, Welch WR, Rosenberg L, Stolley PD, Warshauer ME, et al.  Noncontraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol. 1989;130:1142–1151
  257. Koch M. Risk factors in ovarian cancer of epithelial origin by pathological diagnosis. Br J Cancer. 1989;59:257–258
  258. Gras E, Pons C, Machin P, Matias-Guiu X, Prat J. Loss of heterozygosity at the RB-1 locus and pRB immunostaining in epithelial ovarian tumors: a molecular, immunohistochemical, and clinicopathologic study. Int J Gynecol Pathol. 2001;20:335–340
  259. Fazleabas AT, Brudney A, Gurates B, Chai D, Bulun S. A modified baboon model for endometriosis. Ann N Y Acad Sci. 2002;955:308–317

☆ Reprint requests: Roberta B. Ness, MD, MPH, University of Pittsburgh Graduate School of Public Health, 130 DeSoto St, Room 513 Parran Hall, Pittsburgh, PA 15261. E-mail: repro@vms.cis.pitt.edu

PII: S0002-9378(03)00362-4

doi: 10.1067/mob.2003.408

American Journal of Obstetrics & Gynecology
Volume 189, Issue 1 , Pages 280-294 , July 2003

Article Tools

* Image Usage & Resolution